Impact and mechanism of non-steroidal anti-inflammatory drugs combined with chemotherapeutic drugs on human lung cancer-nude mouse transplanted tumors

Sun,Weiyi; Chen,Gang

doi:10.3892/ol.2016.4493

Impact and mechanism of non-steroidal anti-inflammatory drugs combined with chemotherapeutic drugs on human lung cancer-nude mouse transplanted tumors

Authors:
- Weiyi Sun
- Gang Chen
View Affiliations

Affiliations: Department of Emergency, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China, Department of Respiratory, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China
Published online on: April 25, 2016 https://doi.org/10.3892/ol.2016.4493
Pages: 4193-4199

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the impact of indomethacin treatment combined with oxaliplatin treatment on the expression of cluster of differentiation 44 variant 6 (CD44v6), matrix metalloproteinase-2 (MMP-2) and survivin in human lung cancer‑nude mouse transplanted tumors. The human lung adenocarcinoma (A549)‑nude mouse transplanted tumor model was established, and the mice were divided into a control group, an indomethacin treatment group, an oxaliplatin treatment group and an indomethacin-oxaliplatin combination treatment group. The tumor inhibition rate was calculated following sacrificing of the mice. Immunohistochemical staining and fluorescence reverse transcription‑quantitative polymerase chain reaction were utilized to detect the protein and messenger (m)RNA expression of CD44v6, MMP‑2 and survivin. The tumor inhibition rates of the indomethacin group, the oxaliplatin group and the combination group were 26.67, 47.70 and 68.88%, respectively. The protein and mRNA expression levels of CD44v6, MMP‑2 and survivin in the transplanted tumors of each treatment group were reduced compared with the control group (P<0.05), and those of the combination group were lower compared with the single‑drug treatment groups (P<0.05). Survivin and MMP‑2, MMP‑2 and CD44v6, and MMP‑2 and CD44v6 all exhibited linear positive correlation. The present study provides evidence that the administration of indomethacin alone, or in combination with oxaliplatin, may significantly inhibit the growth of lung cancer‑nude mouse transplanted tumors and the expression of CD44v6, MMP‑2 and survivin inside the tumor. The combination of non‑steroidal anti‑inflammatory drugs with chemotherapeutic drugs may improve the antitumor effects.

View Figures

View References

1	Di Nicolantonio JJ, McCarty MF, Chatterjee S, Lavie CJ and O'Keefe JH: A higher dietary ratio of long-chain omega-3 to total omega-6 fatty acids for prevention of COX-2-dependent adenocarcinomas. Nutr Cancer. 66:1279–1284. 2014. View Article : Google Scholar : PubMed/NCBI
2	Han H, Yang S, Lin SG, Xu CS and Han ZH: Effects and mechanism of downregulation of COX-2 expression by RNA interference on proliferation and apoptosis of human breast cancer MCF-7 cells. Mol Med Rep. 10:3092–3098. 2014.PubMed/NCBI
3	Li M, Tan SY and Wang XF: Paeonol exerts an anticancer effect on human colorectal cancer cells through inhibition of PGE₂ synthesis and COX-2 expression. Oncol Rep. 32:2845–2853. 2014.PubMed/NCBI
4	Harris RE, Casto BC and Harris ZM: Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol. 5:677–692. 2014. View Article : Google Scholar : PubMed/NCBI
5	Shao Y, Sun K, Xu W, Li XL, Shen H and Sun WH: Helicobacter pylori infection, gastrin and cyclooxygenase-2 in gastric carcinogenesis. World J Gastroenterol. 20:12860–12873. 2014. View Article : Google Scholar : PubMed/NCBI
6	Athanassiou-Papaefthymiou M, Shkeir O, Kim D, et al: Evaluation of CD44 variant expression in oral, head and neck squamous cell carcinomas using a triple approach and its clinical significance. Int J Immunopathol Pharmacol. 27:337–349. 2014.PubMed/NCBI
7	Zhao S, He JL, Qiu ZX, Chen NY, Luo Z, Chen BJ and Li WM: Prognostic value of CD44 variant exon 6 expression in non-small cell lung cancer: A meta-analysis. Asian Pac J Cancer Prev. 15:6761–6766. 2014. View Article : Google Scholar : PubMed/NCBI
8	Hua D, Kong W, Zheng X, et al: Potent tumor targeting drug release system comprising MMP-2 specific peptide fragment with self-assembling characteristics. Drug Des Devel Ther. 8:1839–1849. 2014.PubMed/NCBI
9	Kamyab-Hesari K, Mohtasham N, Aghazadeh N, Biglarian M, Memar B and Kadeh H: The expression of MMP-2 and Ki-67 in head and neck melanoma, and their correlation with clinic-pathologic indices. J Cancer Res Ther. 10:696–700. 2014.PubMed/NCBI
10	Budak M, Korpinar MA, Kalkan T and Tuncel H: Mutation detection in the promoter region of survivin gene on N-methyl-N-nitrosourea induced colon tumor model in experiment. Bratisl Lek Listy. 115:554–556. 2014.PubMed/NCBI
11	Abd El-Hakim TF, El-Shafie MK, Abdou AG, Azmy RM, El-Naidany SS and Badr El-Din MO: Value of urinary survivin as a diagnostic marker in bladder cancer. Anal Quant Cytopathol Histpathol. 36:121–127. 2014.PubMed/NCBI
12	Faibish D, Suzuki M and Bartlett JD: Appropriate real-time PCR reference genes for fluoride treatment studies performed in vitro or in vivo. Arch Oral Biol. 62:33–42. 2016. View Article : Google Scholar : PubMed/NCBI
13	Turk HM, Camci C, Sevinc A, Bukyukberber S, Sari I and Adli M: Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer. Asian Pac J Cancer Prev. 13:315–318. 2012. View Article : Google Scholar : PubMed/NCBI
14	Ranger GS: Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors. Anticancer Res. 34:6277–6282. 2014.PubMed/NCBI
15	Quidville V, Segond N, Pidoux E, Cohen R, Jullienne A and Lausson S: Tumor growth inhibition by indomethacin in a mouse model of human medullary thyroid cancer: implication of cyclooxygenases and 15-hydroxyprostaglandin dehydrogenase. Endocrinology. 145:2561–2571. 2004. View Article : Google Scholar : PubMed/NCBI
16	Di Francesco AM, Ruggiero A and Riccardi R: Cellular and molecular aspects of drugs of the future: Oxaliplatin. Cell Mol Life Sci. 59:1914–1927. 2002. View Article : Google Scholar : PubMed/NCBI
17	Avoranta ST, Korkeila EA, Syrjänen KJ, Pyrhönen SO and Sundström JT: Lack of CD44 variant 6 expression in rectal cancer invasive front associates with early recurrence. World J Gastroenterol. 18:4549–4556. 2012. View Article : Google Scholar : PubMed/NCBI
18	Dommann SN, Ziegler T, Dommann-Schener CC, Meyer J, Panizzon R and Burg G: CD44v6 is a marker for systemic spread in cutaneous T-cell lymphomas. A comparative study between nodal and cutaneous lymphomas. J Cutan Pathol. 22:407–412. 1995. View Article : Google Scholar : PubMed/NCBI
19	Liang YZ, Fang TY, Xu HG and Zhuo ZQ: Expression of CD44v6 and Livin in gastric cancer tissue. Chin Med J (Engl). 125:3161–3165. 2012.PubMed/NCBI
20	Protin U, Schweighoffer T, Jochum W and Hilberg F: CD44-deficient mice develop normally with changes in subpopulations and recirculation of lymphocyte subsets. J Immunol. 163:4917–4923. 1999.PubMed/NCBI
21	Matsumura Y and Tarin D: Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet. 340:1053–1058. 1992. View Article : Google Scholar : PubMed/NCBI
22	Indinnimeo M, Cicchini C, Giarnieri E, Stazi A, Mingazzini PL and Stipa V: Evaluation of CD44 variant 6 expression and clinicopathological factors in pulmonary metastases from colon carcinoma. Oncol Rep. 10:1875–1877. 2003.PubMed/NCBI
23	Röcken M: Early tumor dissemination, but late metastasis: Insights into tumor dormancy. J Clin Invest. 120:1800–1803. 2010. View Article : Google Scholar : PubMed/NCBI
24	Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y and Sugimachi K: Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery. 128:408–416. 2000. View Article : Google Scholar : PubMed/NCBI
25	Ko YH, Won HS, Jeon EK, Hong SH, Roh SY, Hong YS, Byun JH, Jung CK and Kang JH: Prognostic significance of CD44s expression in resected non-small cell lung cancer. BMC Cancer. 11:3402011. View Article : Google Scholar : PubMed/NCBI
26	Skubitz AP: Adhesion molecules. Cancer Treat Res. 107:305–329. 2002.PubMed/NCBI
27	Cho HJ, Kim HR, Park YS, Kim YH, Kim DK and Park SI: Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy. Surg Oncol. 24:329–334. 2015. View Article : Google Scholar : PubMed/NCBI
28	Tao YF, Lu J, Du XJ, Sun LC, Zhao X, Peng L, Cao L, Xiao PF, Pang L, Wu D, et al: Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells. BMC Cancer. 12:6192012. View Article : Google Scholar : PubMed/NCBI
29	Andersson SE, Svensson MN, Erlandsson MC, Dehlin M, Andersson KM and Bokarewa MI: Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis. PLoS One. 7:e476682012. View Article : Google Scholar : PubMed/NCBI
30	Jarrin M, Mansergh FC, Boulton ME, Gunhaga L and Wride MA: Survivin expression is associated with lens epithelial cell proliferation and fiber cell differentiation. Mol Vis. 18:2758–2769. 2012.PubMed/NCBI
31	Liu W, Zhu F, Jiang Y, Sun D, Yang B and Yan H: siRNA targeting survivin inhibits the growth and enhances the chemosensitivity of hepatocellular carcinoma cells. Oncol Rep. 29:1183–1188. 2013.PubMed/NCBI
32	MacDonald BT, Tamai K and He X: Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
33	Bongiovanni L, D'Andrea A, Porcellato I, Ciccarelli A, Malatesta D, Romanucci M, Della Salda L, Mechelli L and Brachelente C: Canine cutaneous melanocytic tumours: significance of β-catenin and survivin immunohistochemical expression. Vet Dermatol. 26:270–e59. 2015. View Article : Google Scholar : PubMed/NCBI
34	Katsube K, Sakamoto K, Tamamura Y and Yamaguchi A: Role of CCN, a vertebrate specific gene family, in development. Dev Growth Differ. 51:55–67. 2009. View Article : Google Scholar : PubMed/NCBI
35	Hou CH, Chiang YC, Fong YC and Tang CH: WISP-1 increases MMP-2 expression and cell motility in human chondrosarcoma cells. Biochem Pharmacol. 81:1286–1295. 2011. View Article : Google Scholar : PubMed/NCBI
36	Jiang L, Luo RY, Yang J and Cheng YX: Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells. Mol Med Rep. 7:425–430. 2013.PubMed/NCBI
37	Mao Y, Chen H, Lin Y, Xu X, Hu Z, Zhu Y, Wu J, Xu X, Zheng X and Xie L: microRNA-330 inhibits cell motility by downregulating Sp1 in prostate cancer cells. Oncol Rep. 30:327–333. 2013.PubMed/NCBI